CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (RV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC).


Conference Paper

Full Text

Duke Authors

Cited Authors

  • Venook, AP; Niedzwiecki, D; Lenz, H-J; Innocenti, F; Mahoney, MR; O'Neil, BH; Shaw, JE; Polite, BN; Hochster, HS; Atkins, JN; Goldberg, RM; Mayer, RJ; Schilsky, RL; Bertagnolli, MM; Blanke, CD

Published Date

  • May 20, 2014

Published In

Volume / Issue

  • 32 / 15

Published By


  • 1

Electronic International Standard Serial Number (EISSN)

  • 1527-7755

International Standard Serial Number (ISSN)

  • 0732-183X

Conference Name

  • 50th Annual Meeting of the American-Society-of-Clinical-Oncology

Conference Location

  • Chicago, IL

Conference Start Date

  • May 30, 2014

Conference End Date

  • June 3, 2014